Abstract: N-Piperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxamide and its salts and solvates are powerful antagonists of the CB1 cannabinoid receptors. They are prepared by reacting a functional derivative of 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylic acid with 1-aminopiperidine, optionally followed by salification.

Abstract: The invention relates to an injection device comprising a syringe body (1, 13), which delimits a chamber which is designed to be filled with a liquid, and a unit (17) for distributing the liquid, comprising an end piece (17a) for closing off the chamber, which is extended by a locking male conical connection (17c), and can be displaced axially between a closing-off position of the said chamber and a position for injection of the liquid. According to the invention, the unit (17) for distributing comprises an intermediate connection (20), which is provided between the closing-off end piece (17a) and the male conical connection (17c).

Abstract: Novel orthorombic polymorph of clopidogrel hydrogen sulfate or hydrogen sulfate of methyl (+)-(S)-&agr;-(2-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine-5-acetate and a process for its preparation.

Abstract: The invention relates to a method for the treatment of mood disorders utilizing osanetant or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to: a) methylbiphenyl derivatives of general formula: in which R1 represents OH, C3-C7 alkyl or C3-C7 cycloalkyl, these compounds being in the form of individual isomers or mixtures thereof, b) their preparation by reaction: either of a hydroxylamine salt with an N-substituted o-(p-tolyl)benzaldimine, to give o-(p-tolyl)benzaldoxime or of an N-substituted 2-halobenzaldimine with a p-tolylmagnesium halide in the presence of an inorganic manganese derivative, to give the compounds of formula I in which R1 represents C3-C7 alkyl or C3-C7 cycloalkyl c) their use for the preparation of o-(p-tolyl)-benzonitrile, which is an intermediate in the synthesis of medicinal products.

Abstract: The invention concerns compounds of formula (I) wherein: A represents either a hydrogen atom or a hydroxyl group; B represents a pyrrolidin-2-yl (D) or 2-piperidyl (E), B capable of being substituted by one or two R5 groups; R1 represents a hydrogen atom, a C1-C6 alkyl, a C2-C6 alkenyl, a C1-C2 perfluoroalkyl or a C1-C6 fluoroalkyl group; R2, R3 or R4, independently of one another, represent a hydrogen atom, a C1-C6 alkyl, group or a C2-C6 alkenyl group, or R1 and R2 can together form a C1-C6 alkylene chain, or a C3-C6 alkenylene chain; R5 represents a C1-C6 alkyl group, and R6 represents a hydrogen atom, a C1-C6 alkyl group, a C2-C6 alkenyl group, C3-C6 cycloalkyl, C3-C6 cycloalkenyl or a benzyl.

Abstract: The invention relates to 1,4-diazabicyclo[3.2.2]nonane derivatives, to pharmaceutical compositions containing them, and to methods for the treatment or prevention of disorders associated with a dysfunction of the nicotinic receptors utilizing them.

Abstract: The subject-matter of the invention is a process for the preparation of substituted 4-methylbiphenyls of general formula: in which R is a cyano group or a protected tetrazolyl group of formula: in which R1, situated at the 1 or 2 position of the tetrazolyl group, is a protective group, characterized in that a halobenzene of formula: in which Hal is a halogen atom and R has the same meaning as above, is reacted with a p-tolylmagnesium halide in the presence of a linear or branched polyether and of a catalyst comprising a transition metal.

Abstract: Pyridazino[4,5-b]indole-1-acetamide derivatives for the prevention or treatment of diseases linked to the dysfunctioning of peripheral-type benzodiazepine receptors.

Abstract: The invention relates to a process for preparing (R)-(+)-3-{1-[2-(4-benzoyl-2-(3,4-difluorophenyl)-morpholin-2-yl)ethyl]-4-phenylpiperid-4-yl}-1,1-dimethylurea and the salts, solvates and/or hydrates thereof.

Abstract: The present invention relates to cholecystokinin (CCK)-agonist substituted thiazoles of formula: in which R1 is a substituted phenyl group, R2 is a group chosen from CH2—R7, (CH2)2—R7, S—CH2—R7, CH2—S—R7 and (C5-C8)alkyl with R7 being a (C5-C7)cycloalkyl group, and R3 is a group with R8 being a group (CH2)nR15 or and R15 being COOH or COO(C1-C4)alkyl. The invention also relates to a process for the preparation of the pharmaceutical compositions containing them and to their uses for the preparation of medicines.

Abstract: A method for preparing the potassium dihydrate salt of 2-[[4-(2-chlorophenyl)-2-thiazolyl]carbamoyl]indole-1-acetic acid, by reacting 2-[[4-(2-chlorophenyl)-2-thiazolyl]carbamoyl]indole-1-acetic acid or its C1-C4 alkyl esters with potassium carbonate in a two phase solvent system comprising a mixture of water and an organic solvent which is only slightly miscible with water and optionally recrystallising the precipitated intermediate solvate from water and to the potassium dihydrate salt thus obtained.

Abstract: The invention relates to the use of compounds of formula for the preparation of medicines designed for the treatment of neuronal and cerebral disorders. The invention also relates to the compounds of formula: a process for their preparation and the pharmaceutical compositions containing them.

Abstract: An improved process for preparing (2S)-1-[(2R,3S)-5-chloro-3-(2-chlorophenyl)-1-(3,4-dimethoxybenzenesulphonyl)-3-hydroxy-2,3 -dihydro-1H-indole-2-carbonyl]pyrrolidine-2-carboxamide by cyclization of (2S)-1-{[[4-chloro-2-(2-chlorobenzoyl)phenyl]-(3,4-dimethoxybenzenesulphonyl)amino]acetyl}pyrrolidine-2-carboxamide in the presence of an alkali metal hydroxide in a mixture of polyethylene glycol and water.

Abstract: The invention relates to the use of tetrahydropyridine derivatives of the formula in which: R1 is a halogen or a CF3, (C1-C4)alkyl or (C1-C4)alkoxy group; Y is a nitrogen atom or a CH group; Z′ and Z″ are each hydrogen or a (C1-C3)alkyl group, or one is hydrogen and the other is a hydroxyl group, or the two together are an oxo group; and Z is: a phenyl radical; a phenyl radical monosubstituted by a substituent X, X being: (a) a (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C7)carboxyalkyl, (C1-C4)alkoxycarbonyl(C1-C6)alkyl, (C3-C7)carboxyalkoxy or (C1-C4)alkoxycarbonyl(C1-C6)alkoxy group; (b) a group selected from (C3-C7)cycloalkyl, (C3-C7)cycloalkoxy, (C3-C7)cycloalkylmethyl, (C3-C7)cycloalkylamino and cyclohexenyl, it being possible for said group to be substituted by a halogen, hydroxy, (C1-C4)alkoxy, carboxy, (C1-C4)alkoxycarbonyl, amino or mono- or di-(C1-C4)alkylamino group; or (c) a group selected from phenyl, phenoxy, phenylamino, N—(C1-C3)alkyl-phenylamino, phenylmethy

Abstract: The subject of the invention is the compounds of formula: in which R1, R2, R3, R4, R5 and R6 are as defined in Claim 1. The compounds have a high affinity for CRF receptors.

Abstract: The invention relates to the use of a central cannabinoid receptor antagonist, by itself or in association with a compound for regulating metabolic disorders, especially a &bgr;3-adrenergic receptor agonist, for the preparation of drugs useful in the treatment of appetency disorders.

Abstract: Pharmaceutical compositions containing irbesartan, alone or in combination with a diuretic, providing tablets with a high relative amount of active agent and excellent wetting and disintegration properties.

Abstract: The invention relates to the use of a compound of formula (I): for the preparation of pharmaceutical compositions for increasing the circulating, cellular and extracellular levels of TGF-&bgr;1.

Abstract: This invention relates to 3-(3-phenyl-2,6-dioxopiperidin-3-yl)propionamide derivatives, and to processes for preparing the same.